Shores to Speak on Paragraph IV Litigation at ACI Master Symposium

September 20, 2016
InterContinental Chicago Magnificent Mile Chicago, IL

DC-based Antitrust partner Laura Shores will participate as a panelist in “Revisiting Reverse-Payment Settlements and Antitrust Concerns Impacting Paragraph IV Litigation” on September 20, 2016. This panel is a part of American Conference Institute’s fourth annual Paragraph IV Disputes Master Symposium.

Paragraph IV of the Drug Price Competition and Patent Term Restoration Act, commonly referred to as Hatch-Waxman, enables a company to seek approval from the US Food and Drug Administration to market a generic drug before the expiration of a patent relating to the brand name drug upon which the generic is based.

Laura’s panel will address the following topics:

  • Developing jurisprudence regarding patent settlements post-Actavis
  • What constitutes a payment
  • Differing judicial interpretations of the “Rule of Reason Test”
  • Weighing anticompetitive harm and procompetitive benefits
  • Authorized generics
  • Structuring settlements in light of developing jurisprudence
  • The resurgence of purchaser sham litigation claims
  • The impact of cGMP’s and 483s on leverage and settlements
  • Best strategies to communicate risks and rewards of settlement to clients

This ACI master symposium functions as a “meeting of the minds,” attracting preeminent patent litigators representing brand name and generic drug makers, leading in-house counsel, esteemed jurists and government representatives to discuss, analyze and interpret the latest controversies impacting Paragraph IV litigation.

» Get more information/register for this event.

Subscribe Link

Email Disclaimer